randomized 1
phase 1
ii 1
trial 1
comparing 1
obinutuzumab 1
ga 1
rituximab 1
patients 1
relapsed 1
cd 1
indolent 1
bcell 2
nonhodgkin 1
lymphoma 4
final 1
analysis 1
gauss 1
study 1
gray 1
zone 1
features 1
intermediate 1
between 1
classical 1
hodgkin 1
diffuse 1
large 2
characteristics 1
outcomes 1
prognostication 1
among 1
multicenter 1
cohort 1
